Stefan Knapp

Stefan Knapp

SGC Frankfurt

Knapp

Biography

Prof Stefan Knapp studied Chemistry at the University of Marburg (Germany) and at the University of Illinois (USA). He did his PhD in protein crystallography at the Karolinska Institute in Stockholm (Sweden) (1996) and continued his career at the Karolinska Institute as a postdoctoral scientist (1996-1999). In 1999, he joined the Pharmacia Corporation as a principal research scientist in structural biology and biophysics. He left the company in 2004 to set up a research group at the Structural Genomics Consortium at Oxford University (SGC). From 2008 to 2015 he was a Professor of Structural Biology at the Nuffield Department of Clinical Medicine (NDM) at Oxford University (UK) and between 2012 and 2015 he was the Director for Chemical Biology at the Target Discovery Institute (TDI). He joined Frankfurt University (Germany) in 2015 as a Professor of Pharmaceutical Chemistry and the Buchmann Institute of Molecular Life Sciences. He remains associated to the SGC as a visiting Professor at Oxford and he is also adjunct Professor of the George Washington University. Since 2017 he is the CSO of the newly founded SGC node at the Goethe-University Frankfurt. His research interests are the rational design of selective inhibitors that target protein kinases as well as protein interactions modules that function as reader domains of the epigenetic code.

Research Areas

My laboratory is interested in understanding molecular mechanisms that regulate protein function of key signalling molecules and how these mechanisms can be utilized for the development of highly selective and potent inhibitors (chemical probes). As a basis for this work we have generated a comprehensive set of high resolution crystal structures that cover most members of the protein family of interest. We are particularly interested in protein interactions module of the bromodomain family that specifically recognize ε-N-lysine acetylation motifs, a key event in the reading process of epigenetic marks. This effort generated several highly selective chemical probes targeting bromodomains. A second research focus is on protein kinases. Our laboratory has solved a comprehensive set of crystal structure of this large protein family offering the opportunity to understand molecular mechanisms of their regulation and developing new strategies for their selective targeting. We developed for example a number of highly selective inhibitors by exploring unusual binding modes and allosteric binding sites. A particular focus of the laboratory is also to understand structural mechanisms leading to slow binding kinetics as part of the K4DD consortium.

2022

Enabling pseudokinases as potential drug targets.

Preuss F, Chatterjee D, Dederer V, Knapp S, Mathea S

Methods Enzymol. 2022-5-8 . 667:663-683 .doi: 10.1016/bs.mie.2022.03.050

PMID: 35525558

BET bromodomain inhibitors.

Schwalm MP, Knapp S

Curr Opin Chem Biol. 2022-4-21 . 68:102148 .doi: 10.1016/j.cbpa.2022.102148

PMID: 35462054

Synthesis and biological evaluation of Haspin inhibitors: Kinase inhibitory potency and cellular activity.

Zeinyeh W, Esvan YJ, Josselin B, Defois M, Baratte B, Knapp S, Chaikuad A, Anizon F, Giraud F, Ruchaud S, Moreau P

Eur J Med Chem. 2022-4-9 . 236:114369 .doi: 10.1016/j.ejmech.2022.114369

PMID: 35447555

Kinase domain autophosphorylation rewires the activity and substrate specificity of CK1 enzymes.

Cullati SN, Chaikuad A, Chen JS, Gebel J, Tesmer L, Zhubi R, Navarrete-Perea J, Guillen RX, Gygi SP, Hummer G, Dötsch V, Knapp S, Gould KL

Mol Cell. 2022-3-21 . .doi: 10.1016/j.molcel.2022.03.005

PMID: 35353987

Development of novel urea-based ATM kinase inhibitors with subnanomolar cellular potency and high kinome selectivity.

Dimitrov T, Anli C, Moschopoulou AA, Kronenberger T, Kudolo M, Geibel C, Schwalm MP, Knapp S, Zender L, Forster M, Laufer S

Eur J Med Chem. 2022-3-8 . 235:114234 .doi: 10.1016/j.ejmech.2022.114234

PMID: 35325634

Resistance to kinase inhibition through shortened target engagement.

Rangwala AM, Berger BT, Robers MB, Knapp S, Seeliger MA

Mol Cell Oncol. 2022-3-8 . 9(1):2029999 .doi: 10.1080/23723556.2022.2029999

PMID: 35252553

Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2.

Singh RK, Soliman A, Guaitoli G, Störmer E, von Zweydorf F, Dal Maso T, Oun A, Van Rillaer L, Schmidt SH, Chatterjee D, David JA, Pardon E, Schwartz TU, Knapp S, Kennedy EJ, Steyaert J, Herberg FW, Kortholt A, Gloeckner CJ, Versées W

Proc Natl Acad Sci U S A. 2022-3-1 . 119(9): .doi: 10.1073/pnas.2112712119

PMID: 35217606

LRRK2 dynamics analysis identifies allosteric control of the crosstalk between its catalytic domains.

Weng JH, Aoto PC, Lorenz R, Wu J, Schmidt SH, Manschwetus JT, Kaila-Sharma P, Silletti S, Mathea S, Chatterjee D, Knapp S, Herberg FW, Taylor SS

PLoS Biol. 2022-2-23 . 20(2):e3001427 .doi: 10.1371/journal.pbio.3001427

PMID: 35192607

Image-Based Annotation of Chemogenomic Libraries for Phenotypic Screening.

Tjaden A, Chaikuad A, Kowarz E, Marschalek R, Knapp S, Schröder M, Müller S

Molecules. 2022-2-21 . 27(4): .doi: 10.3390/molecules27041439

PMID: 35209227

Cascade Synthesis of Kinase-Privileged 3-Aminoindazoles via Intramolecular N-N Bond Formation.

Zhu WF, Krämer A, Knapp S, Proschak E, Hernandez-Olmos V

J Org Chem. 2022-2-18 . .doi: 10.1021/acs.joc.1c03057

PMID: 35179025